CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 119 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $28,385 | +2645.2% | 1,903,701 | +1916.2% | 0.00% | – |
Q2 2023 | $1,034 | +63.1% | 94,421 | +30.0% | 0.00% | – |
Q1 2023 | $634 | -21.8% | 72,611 | -43.9% | 0.00% | – |
Q4 2022 | $811 | -99.9% | 129,417 | -26.1% | 0.00% | – |
Q3 2022 | $613,000 | +70.3% | 175,100 | +43.3% | 0.00% | – |
Q2 2022 | $360,000 | +5.3% | 122,200 | +11.0% | 0.00% | – |
Q1 2022 | $342,000 | +4.6% | 110,123 | +13.9% | 0.00% | – |
Q4 2021 | $327,000 | -34.9% | 96,651 | -29.7% | 0.00% | – |
Q3 2021 | $502,000 | -16.3% | 137,574 | 0.0% | 0.00% | – |
Q2 2021 | $600,000 | +90.5% | 137,574 | +98.4% | 0.00% | – |
Q1 2021 | $315,000 | +14.5% | 69,335 | +44.6% | 0.00% | – |
Q4 2020 | $275,000 | +60.8% | 47,958 | +103.6% | 0.00% | – |
Q3 2020 | $171,000 | -96.2% | 23,558 | -94.3% | 0.00% | -100.0% |
Q3 2018 | $4,554,000 | -50.6% | 410,967 | -40.2% | 0.00% | 0.0% |
Q2 2018 | $9,223,000 | +1.4% | 687,277 | -1.8% | 0.00% | 0.0% |
Q1 2018 | $9,094,000 | – | 700,100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |